Lethal immunotoxicity in high-dose systemic AAV therapy.

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Systemic gene therapy with adeno-associated virus (AAV) is being investigated for inherited diseases.
• While successful in some conditions like spinal muscular atrophy, high-dose AAV therapy has led to fatalities from organ failure.
• Immune responses to the AAV vector and host factors are implicated in this toxicity.

Purpose of the Study:

• To review clinical findings related to fatalities in high-dose systemic AAV gene therapy.
• To highlight the role of immunotoxicity in AAV gene therapy-associated adverse events.
• To advocate for collaborative efforts to elucidate and mitigate AAV-induced lethality.

Main Methods:

• Review of clinical trial data and published literature on systemic AAV gene therapy.
• Analysis of reported adverse events, focusing on fatalities and organ failures.
• Examination of the immunological mechanisms contributing to vector toxicity.

Main Results:

• Fatalities have occurred due to liver, kidney, heart, or lung failure following high-dose systemic AAV gene therapy.
• Innate and adaptive immune responses to the AAV vector are critical determinants of toxicity.
• Patient-specific host factors also contribute to the risk of severe adverse events.

Conclusions:

• Understanding the mechanisms of AAV-induced immunotoxicity is essential for improving patient safety.
• Concerted efforts are needed from researchers, clinicians, and regulatory bodies to develop preventative and therapeutic strategies.
• Mitigating immune responses is key to realizing the full potential of systemic AAV gene therapy for inherited disorders.